Thilo Hackert
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Background Complete surgical resection (R0 resection) is crucial for overall and disease-free survival in patients with pancreatic cancer undergoing curative surgery. The radical antegrade modular pancreatosplenectomy (RAMPS) procedure was developed to increase achievement of R0 resection margins for tumour resections of the pancreatic body and tail. By extending the posterior dissection plane, a more radical surgical resection can be achieved, as this is the most frequent site of positive margins in conventional left pancreatectomy. RAMPS includes a standardized lymph node dissection and early control of the splenic vessels. Feasibility and safety have already been demonstrated and retrospective studies have shown promising results regarding higher proportions of R0 resection and lymph node counts. To date, high-quality evidence from randomized clinical trials investigating the oncological benefit of RAMPS (that is, resection margin status, disease-free and overall survival) for this patient cohort is lacking. Methods The RAMPS trial is a multicentre, randomized clinical, patient and assessor-blinded, confirmatory, superiority trial. In all, 122 patients with an indication for left pancreatectomy due to malignancy of the pancreatic body or tail will be required in each study arm to achieve 80% power at a significance level of 0.025; patients will be randomized to either the RAMPS approach or conventional left pancreatectomy in a 1 : 1 ratio. Patients will be recruited over a 30-month enrolment period. The primary outcome will be the achievement of R0 resections. Secondary outcomes include survival and surgical, functional, and patient-reported outcomes with a 3-year follow-up. Conclusion The primary objective of the RAMPS trial is to demonstrate the superiority of the RAMPS approach over standard left pancreatectomy in improving the achievement of R0 resection and, consequently, long-term oncological patient outcomes. RAMPS could be established as the new surgical standard for tumour resection in patients with pancreatic cancer in the body or tail of the pancreas. Registration number: DRKS00033031 (https://www.bfarm.de/EN/BfArM/Tasks/German-Clinical-Trials-Register/_node.html).
Year:
2025
Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data
Year:
2025
Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data
Year:
2025
Background Patients undergoing hepato-pancreato-biliary surgery are typically preoperatively assessed using the American Society of Anesthesiologists (ASA) classification, which is also used for case-mix adjustment when comparing centre outcomes. Studies determining the inter-rater variability of the ASA classification within hepato-pancreato-biliary surgery are currently lacking. Methods An international survey was collected and a case-vignette study was performed (November 2022–April 2023) regarding the ASA classification in patients undergoing hepato-pancreato-biliary surgery among anaesthesiologists and surgeons from (inter)national societies. The survey consisted of 23 questions and eight case-vignettes. Primary analysis included descriptive statistics and the inter-rater variability was calculated using Light's Kappa. Results Overall, 1283 participants from 55 countries responded: 1073 (84%) anaesthesiologists and 210 (16%) surgeons. The ASA classification was commonly used, both clinically 1003/1283 (78%) and for research 728/762 (96%). The majority of respondents (n = 1019, 79%) declared that ASA score impacted their perioperative strategy. There inter-rater variability was fair–moderate (Kappa 0.26–0.42) in all case-vignettes. Inter-rater variability differed within and among geographic regions for each case. Over 80% (n = 1138) of respondents stated that they would take the underlying disease (for example cancer) into account, but this changed the preferred ASA score within the case-vignettes by only 1%. Type of surgery changed the preferred score in the case-vignettes (13% difference). The most common suggestions to improve the ASA classification were to clarify whether type of operation should be considered, create a more extensive definition, and provide more examples. Conclusions Inter-rater variability was present within the ASA classification of patients undergoing hepato-pancreato-biliary surgery, which may impact perioperative strategy and hamper research results. Additional guidance to classify patients according to ASA is urgently needed. Until then, more objective measurements should be considered for case-mix adjustment within research.
Year:
2024
Purpose Even today, it remains a challenge for healthcare professionals to decide whether a clinically stable patient who is recovering from uncomplicated medium or major surgery would benefit from a postoperative intensive care unit (ICU) admission, or whether they would be at least as adequately cared for by a few hours of monitoring in the post-operative care unit (PACU). Methods In this monocentric retrospective observational study, all adult patients who (I) underwent medium or major surgery between 1 January 1 2014 and 31 December 2018 at the Heidelberg University Surgical Center, and (II) were monitored for 1–12 h in the PACU, and then (III) transferred to a normal ward (NW) immediately thereafter were included. At the end of the PACU stay, each patient was cleared by both a surgeon and an anesthesiologist to be transferred to a NW. The first objective of this study was to determine the prevalence of relevant early complications (RECs) within the first 24 h on a normal ward. The secondary objective was to determine the prevalence of RECs in the subgroup of included patients who underwent partial pancreaticoduodenectomy. Results A total of 10,273 patients were included in this study. The prevalence of RECs was 0.50% (confidence interval [CI] 0.40–0.60%), with the median length of stay in the PACU before the patient’s first transfer to a NW being 285 min (interquartile range 210–360 min). In the subgroup of patients who underwent partial pancreaticoduodenectomy ( n = 740), REC prevalence was 1.1% (CI = 0.55–2.12%). Conclusion Based on a medical case-by-case assessment, it is possible to select patients who after a PACU stay of only up to 12 h have a low risk of emergency readmission to an ICU within the 24 h following the transfer to the NW. Continued research will be needed to further improve transfer decisions in such low-risk subgroups.
Year:
2024
Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data
Year:
2024
Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data
Year:
2024
Background: There are conflicting data on whether nonalcoholic fatty liver disease (NAFLD) is associated with susceptibility to pancreatic cancer (PC). Using Mendelian randomization (MR), we investigated the relationship between genetic predisposition to NAFLD and risk for PC. Methods: Data from genome-wide association studies within the Pancreatic Cancer Cohort Consortium (PanScan; cases n=5090, controls n=8733) and the Pancreatic Cancer Case Control Consortium (PanC4; cases n=4,163, controls n=3,792) were analyzed. We used data on 68 genetic variants with four different MR methods (inverse variance weighting [IVW], MR-Egger, simple median, and penalized weighted median) separately to predict genetic heritability of NAFLD. We then assessed the relationship between each of the four MR methods and PC risk, using logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for PC risk factors, including obesity and diabetes. Results: No association was found between genetically predicted NAFLD and PC risk in the PanScan or PanC4 samples (e.g., PanScan, IVW OR=1.04, 95% CI: 0.88-1.22, MR-Egger OR=0.89, 95% CI: 0.65-1.21; PanC4, IVW OR=1.07, 95% CI: 0.90-1.27, MR-Egger OR=0.93, 95% CI: 0.67-1.28). None of the four MR methods indicated an association between genetically predicted NAFLD and PC risk in either sample. Conclusions: Genetic predisposition to NAFLD is not associated with PC risk. Impact: Given the close relationship between NAFLD and metabolic conditions, it is plausible that any association between NAFLD and PC might reflect host metabolic perturbations (e.g., obesity, diabetes, or metabolic syndrome) and does not necessarily reflect a causal relationship between NAFLD and PC.
Year:
2024
Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data
Year:
2024
Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data
Year:
2024
Year:
2024
Year:
2023
Collaborators (42)
Rayjean Hung
University of Toronto
Neal Freedman
Branch Chief
National Cancer Institute
Bas Groot Koerkamp
Full professor
Erasmus University Rotterdam
Rosa Klotz
University Hospital Heidelberg
Christopher A. Haiman
University of Southern California
Markus W. Büchler
Heidelberg University
Ian M. Thompson
University of Texas Health Science Center at San Antonio
Xiao‐Ou Shu
Vanderbilt University Medical Center
Lynne Wilkens
Professor
University of Hawaii at Manoa
Anne Tjonneland
Professor
Københavns Universitet
Thorsten Brenner
Head of Department & Chairman
University Hospital Essen
Luca Antonio Aldrighetti
Professore/Primario
Università Vita Salute San Raffaele
Ulrike Peters
Fred Hutchinson Cancer Research Center
Timothy M. Pawlik
The Ohio State University Wexner Medical Center
Wei Zheng
-
Miquel Porta
-
Peter Kraft
Professor
Harvard T.H. Chan School of Public Health
Kari Rabe
Assistant Professor of Biostatistics
Mayo Clinic
Stephen Chanock
National Institutes of Health
Alison Klein
Professor
-
John Windsor
Professor
University of Auckland
Federico Canzian
Group Leader
Deutsches Krebsforschungszentrum
Herbert Yu
Researcher/Professor
University of Hawaii at Manoa
Martijn C.G.J. Brouwers
-
Elio Riboli
Professor of Cancer Epidemiology
Imperial College London
Rachael Solomon
Senior Eoidemiologist
Division of Cancer Epidemiology and Genetics, National Cancer Institute
Jean Wactawki-Wende
Dean, Suny Distinguished Professor
University at Buffalo
Malin Sund
Professor/Consultant
University of Helsinki
Marc Besselink
Professor of Pancreatic and Hepatobiliary (HPB) surgery
Amsterdam UMC
Loic Le Marchand
Professor
University of Hawaii
Donghui Li
Professor
The University of Texas MD Anderson Cancer Center
Dittmar Böckler
Chair and Head of Department
University Hospital Heidelberg
Anne Zeleniuch-Jacquotte
Professor of Population Health and Environmental Medicine
NYU School of Medicine
Felix J Hüttner
-
Alan Arslan
Associate Professor
NYU Langone Medical Center
Nuria Malats
Group Leader
Centro Nacional de Investigaciones Oncológicas
Kala Visvanathan
Professor
Johns Hopkins University
Manal M. Hassan
Professor
The University of Texas MD Anderson Cancer Center
Veronica Setiawan
Associate Professor
University of Southern California
Charles Kooperberg
Fred Hutchinson Cancer Research Center
Graham Giles
Head of Research
-
Manolis Kogevinas
Senior Researcher
Barcelona Institute for Global Health
Make your next move.
Prepare your application
Review drafts before you send them.